SCHEDULE: Adage Capital Discloses 5.45% Stake in Tango Therapeutics
Beneficial Ownership Report
Adage Capital Management, L.P. and its principals, Robert Atchinson and Phillip Gross, have disclosed a beneficial ownership of 5.45% in Tango Therapeutics, Inc. common stock.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, collectively reported beneficial ownership of 5,905,349 shares of Tango Therapeutics, Inc. Common Stock.
- This ownership represents 5.45% of the company's outstanding Common Stock.
- The percentage is calculated based on 108,394,190 shares of Common Stock outstanding as of May 5, 2025, as reported in Tango Therapeutics' Quarterly Report on Form 10-Q filed on May 12, 2025.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The disclosure of a new significant institutional ownership stake is generally viewed as a neutral to slightly positive development, indicating investor interest and confidence, though the filing itself provides no operational or financial performance data.
Positives
- The disclosure of a significant stake by an institutional investor like Adage Capital Management, L.P. may signal confidence in Tango Therapeutics' long-term prospects.
- The acquisition of shares in the ordinary course of business suggests a strategic investment rather than an activist play, potentially indicating stability.
Risks
- The filing itself does not detail specific risks related to Tango Therapeutics' operations or financial health, as it is a beneficial ownership report.
Future Outlook
The filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding Tango Therapeutics' future performance or strategic direction.
Industry Context
This filing indicates continued institutional interest in the biotechnology sector, specifically in companies like Tango Therapeutics. The acquisition of a significant stake by a prominent investment firm like Adage Capital Management, L.P. can be viewed as a positive signal within the competitive biotech landscape, where investor confidence is crucial for funding and development.
Stakeholder Impact
- Shareholders may view the entry of a new significant institutional investor positively, potentially boosting confidence in the stock.
- The company's management might perceive this as validation of their strategy and a stable long-term investor.
Key Dates
| Date | Description |
|---|---|
| 2025-05-05 | Date as of which 108,394,190 shares of Common Stock were outstanding, used for percentage calculation. |
| 2025-05-12 | Date Tango Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025, reporting outstanding shares. |
| 2025-06-30 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-08-12 | Date the Schedule 13G was signed and filed by the Reporting Persons. |
Keywords
Tango Therapeutics, Adage Capital Management, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investor, Biotechnology, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.